| Literature DB >> 34836338 |
Andrea Da Porto1, Carlo Tascini2, Maddalena Peghin2, Emanuela Sozio2, Gianluca Colussi1, Viviana Casarsa1, Luca Bulfone1, Elena Graziano2, Chiara De Carlo2, Cristiana Catena1, Leonardo A Sechi1.
Abstract
BACKGROUND: Little is known on the clinical relevance of the nutritional status and body composition of patients hospitalized with SARS-CoV-2 infection. The aim of our study was to assess the prevalence of malnutrition in patients with COVID-19 pneumonia using bioelectrical impedance vector analysis (BIVA), and to evaluate the relationship of their nutritional status with the severity and outcome of disease.Entities:
Keywords: BIVA; COVID-19; bioelectrical impedance vector analysis; low cellular mass; malnutrition
Mesh:
Year: 2021 PMID: 34836338 PMCID: PMC8621574 DOI: 10.3390/nu13114085
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1R/Xc graph provided by bioimpedance vector analysis according to the method of Piccoli et al. [12]. Patients were classified as malnourished when the tip of the impedance vector was within the lower right quadrant outside the 75th percentile of the tolerance ellipse along the horizontal axis (black dot in the figure).
Baseline clinical characteristics and laboratory data.
| Variable | All Patients | No Malnutrition ( | Malnutrition | |
|---|---|---|---|---|
| Age (years) | 69 (58–78) | 66 (57–75) | 77 (71–83) | <0.001 |
| Male Sex (%) | 68.7% (103) | 69.1% (78) | 67.6% (25) | 0.860 |
| BMI (kg/m2) | 28.3 ± 4.9 | 29.3 ± 5.1 | 25.2 ± 3.4 | <0.001 |
| Waist Circ (cm) | 102 ± 16 | 104 ± 14 | 96 ± 11 | 0.001 |
| CRP (mg/dL) | 90.3 ± 71.4 | 86.7 ± 70.4 | 101.8 ± 74.4 | 0.145 |
| Current Smoker (%) | 3.4 | 2.7 | 3.6 | 0.237 |
| Dyslipidemia (%) | 26.2 | 26.8 | 24.3 | 0.957 |
| Hypertension (%) | 55.1 | 56.3 | 51.4 | 0.604 |
| Diabetes (%) | 28.8 | 27.7 | 32.4 | 0.570 |
| COPD (%) | 3.3 | 2.7 | 5.4 | 0.508 |
| CV disease (%) | 25.5 | 21.4 | 37.8 | 0.025 |
| CKD (%) | 12.6 | 10.7 | 16.6 | 0.126 |
| Malignancies (%) | 10.7 | 8 | 18 | 0.064 |
| Liver disease (%) | 6.7 | 6.3 | 8.3 | 0.187 |
| PCT (ng/mL) | 0.34 | 0.89 | 0.16 | 0.120 |
| IL-6 (ng/mL) | 66.5 ± 83.7 | 63.8 ± 63.9 | 72.2 ± 117.5 | 0.440 |
| Pro-ADM (ng/mL) | 1.22 ± 0.93 | 1.09 ± 0.45 | 1.61 ± 1.61 | 0.012 |
| D-Dimer (ng/mL) | 1584 ± 4025 | 1344.7 ± 3951.7 | 2309 ± 4217.2 | 0.025 |
| BUN (mg/dL) | 24.7 ± 10.1 | 22.6 ± 10.8 | 25.4 ± 10.8 | 0.712 |
| Creatinine (mg/dL) | 1.2 ± 1.8 | 1.1 ± 0,4 | 1.5 ± 2.3 | 0.667 |
| Sodium (mEq/L) | 138.2 ± 4.1 | 138.5 ± 3.7 | 137.2 ± 4.6 | 0.073 |
| Potassium (mEq/L) | 4.13 ± 0.5 | 4.12 ± 0.5 | 4.15 ± 0.5 | 0.853 |
| Chloride (mEq/L) | 100.4 ± 4.8 | 100.2 ± 4.2 | 101.2 ± 6.4 | 0.699 |
| AST (UI/L) | 41 ± 26.4 | 41.1 ± 26 | 37.6 ± 21.3 | 0.705 |
| ALT (UI/L) | 42.3 ± 36.3 | 44.7 ± 39.3 | 34.4 ± 23.9 | 0.156 |
| Bilirubin (mg/dL) | 0.568 ± 0.29 | 0.59 ± 0.31 | 0.48 ± 0.19 | 0.081 |
| LDH (UI/L) | 651.8 ± 241.9 | 640.4 ± 240.5 | 686.9 ± 246.5 | 0.328 |
| CPK (UI/L) | 155.3 ± 218.4 | 170.1 ± 230.2 | 110.2 ± 172.8 | 0.102 |
| Troponin (ng/mL) | 17.4 ± 16.2 | 16.7 ± 15.1 | 19.6 ± 9 | 0.133 |
| Albumin (g/L) | 34.4 ± 4.1 | 34.8 ± 4.1 | 33.1 ± 3.3 | 0.020 |
| Uric Acid (mg/dL) | 4.7 ± 1.8 | 4.8 ± 1.6 | 4.6 ± 2.2 | 0.457 |
| Cholesterol (mg/dL) | 150.2 ± 36.7 | 157.5 ± 30.7 | 147.6 ± 38.3 | 0.328 |
| HDL (mg/dL) | 33.4 ± 9.5 | 34.9 ± 8.9 | 32.8 ± 9.7 | 0.207 |
| LDL (mg/dL) | 84.8 ± 30.9 | 90.9 ± 25.8 | 82.7 ± 32.3 | 0.442 |
| TG (mg/dL) | 165.2 ± 58.8 | 165.9 ± 60.9 | 163.3 ± 53.4 | 0.729 |
| Glucose (mg/dL) | 130.9 ± 58.1 | 130.4 ± 57.5 | 132.4 ± 60.6 | 0.849 |
| HbA1c (DCCT) | 6.6 ± 1.1 | 6.5 ± 0.9 | 6.6 ± 1.2 | 0.950 |
IQR, interquartile range; COPD, chronic obstructive pulmonary disease; CKD, chronic kidney disease; CRP, C-reactive protein; PCT, procalcitonin; Pro-ADM, proadrenomedullin; BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactic dehydrogenase; CPK, creatin-phosphokinase; HDL, high density lipoprotein; LDL, low density lipoprotein.
Body composition data obtained by bioimpedance analysis in the study patients.
| Variable | All Patients | No Malnutrition | Malnutrition | |
|---|---|---|---|---|
| Fat mass (kg/m2) | 28.8 ± 10.1 | 28.2 ± 10.6 | 30.5 ± 8.3 | 0.293 |
| Visceral adipose tissue (lt) | 3.4 ± 2.1 | 3.7 ± 2.2 | 2.8 ± 1.5 | 0.037 |
| Fat free mass (kg/m2) | 59.1 ± 13.3 | 62.1 ± 13.1 | 49.9 ± 9.3 | <0.001 |
| Skeletal muscle mass (kg/m2) | 27.1 ± 8.4 | 29.1 ± 8.2 | 20.9 ± 5.7 | <0.001 |
| TBW | 44.6 ± 10.1 | 46.3 ± 10 | 37.0 ± 6.6 | <0.001 |
| EBW | 12.2 ± 3.9 | 20.4 ± 3.9 | 17.3 ± 2.5 | <0.001 |
| EBW/TBW | 45.1 ± 3.3 | 44.4 ± 3.2 | 47 ± 2.7 | <0.001 |
| Phase angle (°) | 5.5 ± 1.5 | 5.9 ± 1.5 | 4.5 ± 0.7 | <0.001 |
TBW, total body water; EBW, extracellular body water.
Clinical severity of COVID 19 pneumonia (WHO stage), lung CT scan involvement, and outcome variables in the study patients. IMV: invasive mechanical ventilation.
| Variable | All Patients | No Malnutrition | Malnutrition ( | |
|---|---|---|---|---|
| WHO stage | ||||
| 0 | 13.3% (20) | 14.2% (16) | 10.8% (4) | 0.738 |
| 1 | 33.3% (50) | 36.3% (41) | 24.3% (9) | 0.229 |
| 2 | 38.6% (58) | 37.1% (42) | 43.2% (16) | 0.562 |
| 3 | 14.8% (22) | 12.4% (14) | 21.7% (8) | 0.185 |
| Lung CT Extension | ||||
| <25% | 9.6% (15) | 9.3% (11) | 10.8% (4) | 0.986 |
| 25–50% | 37.5% (56) | 42.7% (45) | 24.1% (9) | 0.114 |
| 50–75% | 49% (73) | 45.3% (51) | 58.5% (22) | 0.227 |
| >75% | 3.8% (6) | 2.7% (4) | 6.4% (2) | 0.310 |
| Mortality (60 days) (%) | 14.7% (22) | 7.9% (9) | 35.1% (13) | 0.001 |
| IMV (%) | 15.3% (23) | 11.5% (13) | 27.1% (10) | 0.023 |
| Hospital stay (days) | 14.5 ± 15.1 | 13.2 ± 14.8 | 18.2 ± 15.7 | 0.003 |
IMV, invasive mechanical ventilation.
Figure 2Invasive mechanical ventilation free survival at 60 days.
Figure 3Overall survival at 60 days.
Cox proportional hazard ratio for need of mechanical ventilation at 60 days. Crude and correct for covariates.
| Variable | Value | Standard Error | Wald | Pr > Chi2 | Hazard Ratio | Lower Bound (95%) | Upper Bound (95%) |
|---|---|---|---|---|---|---|---|
| BIVA Malnutrition (crude) | 1.122 | 0.421 | 7.086 | 0.008 | 3.069 | 1.344 | 7.009 |
| BIVA Malnutrition (adjusted) * | 1.476 | 0.513 | 8.275 | 0.004 | 4.375 | 1.601 | 11.959 |
| Phase Angle value (adjusted) * | 0.007 | 0.176 | 0.002 | 0.967 | 1.007 | 0.714 | 1.422 |
* Adjusted for age, sex, and BMI.
Cox proportional hazard ratio for death at 60 days. Crude and correct for covariates.
| Variable | Value | Standard Error | Wald | Pr > Chi2 | Hazard Ratio | Lower Bound (95% | Upper Bound (95%) |
|---|---|---|---|---|---|---|---|
| BIVA Malnutrition (crude) | 1.641 | 0.434 | 14.287 | 0.000 | 5.159 | 2.203 | 12.081 |
| BIVA Malnutrition (adjused) * | 1.498 | 0.516 | 8.421 | 0.004 | 4.474 | 1.626 | 12.306 |
| Phase Angle value (adjused) * | 0.081 | 0.153 | 0.280 | 0.597 | 1.084 | 0.803 | 1.463 |
* Adjusted for age, sex, and BMI.